Does reducing benzodiazepines (BZD) improve the efficacy of Electroconvulsive Therapy (ECT) in adults with severe depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Benzodiazepines and ECT Efficacy

Yes, benzodiazepines reduce ECT efficacy, particularly for right unilateral ECT, and should be discontinued prior to treatment when clinically feasible. 1, 2

Evidence for Reduced Efficacy

The impact of benzodiazepines on ECT outcomes depends critically on the type of ECT electrode placement used:

Unilateral ECT

  • One prospective RCT and three large retrospective studies demonstrate that benzodiazepines significantly compromise the efficacy of unilateral ECT 2
  • A case report documented minimal symptomatic improvement with right unilateral ultrabrief ECT while a patient was taking flurazepam and pregabalin, but achieved remission after discontinuation of these medications 2
  • This electrode-specific effect is clinically significant because right unilateral ECT is increasingly preferred due to fewer cognitive side effects 3

Bilateral ECT

  • The same studies found no association between benzodiazepine use and reduced efficacy for bilateral ECT 2
  • One retrospective study of 90 patients receiving bitemporal ECT found benzodiazepine dose was not associated with changes in Hamilton Depression Rating Scale scores 4
  • Paradoxically, one 2019 study reported higher remission rates (81.2% vs 52.0%) in patients receiving concomitant benzodiazepines with bilateral ECT using dose-titration method, though this contradicts the broader literature 5

Mechanism of Interference

Seizure Parameters

  • Benzodiazepines consistently decrease seizure duration across multiple studies 2
  • Most evidence shows no association with increased seizure threshold, contrary to what would be expected pharmacologically 2
  • The clinical impact appears less pronounced than predicted by their anticonvulsant properties alone 2

Clinical Recommendations

Medication Management Strategy

  • The American College of Psychiatry recommends discontinuing benzodiazepines, lithium, and carbamazepine prior to ECT due to risks of adverse effects 1
  • This recommendation takes precedence even though some individual studies show conflicting results 4, 5

When Discontinuation May Not Be Feasible

  • If benzodiazepines cannot be safely discontinued (e.g., severe alcohol or benzodiazepine withdrawal), bilateral electrode placement should be strongly preferred over unilateral 2
  • The ESMO guidelines note benzodiazepines are the treatment of choice for alcohol or benzodiazepine withdrawal delirium, which may necessitate continuation during ECT in select cases 6

Important Caveats

Dosing Method Considerations

  • Studies showing no effect used half-age dosing or dose-titration methods, which may not generalize to fixed high-dose protocols 4, 5
  • Higher benzodiazepine doses may have greater negative impact, though this remains understudied 2

Population-Specific Effects

  • Results may not generalize to populations less responsive to ECT or those with different underlying diagnoses 4
  • The interaction between treatment resistance and benzodiazepine use remains incompletely characterized 7

Anticonvulsants

  • Evidence for anticonvulsants (pregabalin, carbamazepine, valproate) is more mixed, with varied and contradictory results on seizure parameters and efficacy 2
  • Only one of five major studies showed anticonvulsants decrease ECT efficacy, suggesting a weaker effect than benzodiazepines 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.